Drugs / ATSN-101
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03920007 | Sep 2019 → May 2023 overdue | Leber congenital amaurosis 1 | Atsena Therapeutics Inc. | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ATSN-101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03920007 ↗ |
| Route | Other | “Route of administration: Subretinal injection” NCT03920007 ↗ |